OBJECTIVE: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. METHODS: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. RESULTS: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. CONCLUSIONS: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.
OBJECTIVE: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. METHODS: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. RESULTS: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. CONCLUSIONS: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.
Authors: Catherine M Bender; John D Merriman; Amanda L Gentry; Gretchen M Ahrendt; Sarah L Berga; Adam M Brufsky; Frances E Casillo; Meredith M Dailey; Kirk I Erickson; Frances M Kratofil; Priscilla F McAuliffe; Margaret Q Rosenzweig; Christopher M Ryan; Susan M Sereika Journal: Cancer Date: 2015-04-23 Impact factor: 6.860
Authors: Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard Journal: Breast Cancer Res Treat Date: 2010-11-03 Impact factor: 4.872
Authors: Feng Liu; Mark Day; Luis C Muñiz; Daniel Bitran; Robert Arias; Raquel Revilla-Sanchez; Steve Grauer; Guoming Zhang; Cody Kelley; Virginia Pulito; Amy Sung; Ronald F Mervis; Rachel Navarra; Warren D Hirst; Peter H Reinhart; Karen L Marquis; Stephen J Moss; Menelas N Pangalos; Nicholas J Brandon Journal: Nat Neurosci Date: 2008-02-24 Impact factor: 24.884
Authors: Marc G Berman; Mary K Askren; Misook Jung; Barbara Therrien; Scott Peltier; Douglas C Noll; Min Zhang; Lynn Ossher; Daniel F Hayes; Patricia A Reuter-Lorenz; Bernadine Cimprich Journal: Health Psychol Date: 2013-08-05 Impact factor: 4.267
Authors: Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles Journal: Semin Oncol Date: 2013-12 Impact factor: 4.929
Authors: K Ribi; J Aldridge; K-A Phillips; A Thompson; V Harvey; B Thürlimann; F Cardoso; O Pagani; A S Coates; A Goldhirsch; K N Price; R D Gelber; J Bernhard Journal: Br J Cancer Date: 2012-04-24 Impact factor: 7.640
Authors: Lynne I Wagner; Robert J Gray; Joseph A Sparano; Timothy J Whelan; Sofia F Garcia; Betina Yanez; Amye J Tevaarwerk; Ruth C Carlos; Kathy S Albain; John A Olson; Matthew P Goetz; Kathleen I Pritchard; Daniel F Hayes; Charles E Geyer; E Claire Dees; Worta J McCaskill-Stevens; Lori M Minasian; George W Sledge; David Cella Journal: J Clin Oncol Date: 2020-04-09 Impact factor: 44.544
Authors: Bethany D Nugent; Catherine M Bender; Susan M Sereika; Jean M Tersak; Margaret Rosenzweig Journal: J Adolesc Young Adult Oncol Date: 2017-08-07 Impact factor: 2.223
Authors: Catherine M Bender; John D Merriman; Susan M Sereika; Amanda L Gentry; Frances E Casillo; Theresa A Koleck; Margaret Q Rosenzweig; Adam M Brufsky; Priscilla McAuliffe; Yehui Zhu; Yvette P Conley Journal: Oncol Nurs Forum Date: 2018-05-01 Impact factor: 2.172
Authors: Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi Journal: J Pain Symptom Manage Date: 2020-01-15 Impact factor: 3.612
Authors: Michelle C Janelsins; Charles E Heckler; Luke J Peppone; Tim A Ahles; Supriya G Mohile; Karen M Mustian; Oxana Palesh; Ann M O'Mara; Lori M Minasian; Annalynn M Williams; Allison Magnuson; Jodi Geer; Shaker R Dakhil; Judith O Hopkins; Gary R Morrow Journal: J Clin Oncol Date: 2018-09-21 Impact factor: 44.544